AI-generated analysis. Always verify with the original filing.
SCYNEXIS, Inc. completed the acquisition of Poxel SA's AMP kinase activator program, including PXL-770 (now SCY-770) for ADPKD, for an $8 million upfront payment and up to $188 million in milestones.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Asset Purchase Agreement On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxe
Completion of Acquisition or Disposition of Assets. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.01. Item 7
, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the
Financial Statements and Exhibits. (d) Exhibits. Exhibit No.: 99.1 | Description: Press release of the Company dated March 31, 2026 Exhibit No.: 104 | Descripti
Acquisition / Disposition
Material Agreement